ストックスクリーナーアプリを入手
351.81
0.94%
-3.34
Praxis Precision Medicines Inc (PRAX) 最新ニュース
PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative
Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria
Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo
Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia
Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances - simplywall.st
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest? - Yahoo Finance
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800 - Moomoo
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Praxis: Commercial Launch Could Smash Expectations (Video) - Seeking Alpha
RBC Adjusts PT on Praxis Precision Medicines to $462 From $449, Keeps Outperform Speculative Risk Rating - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines PT to $475 From $374, Maintains Buy Rating - marketscreener.com
Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotech Powerhouse with 71.91% Upside Potential - DirectorsTalk Interviews
Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Q2 Earnings Call Highlights - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Estimates By $0.80 EPS - marketbeat.com
PD Small-Cap Value Index Portfolio's Praxis Precision Medicines Inc(PRAX) Holding History - GuruFocus
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Hi - GuruFocus
Wedbush Adjusts PT on Praxis Precision Medicines to $188 From $162, Maintains Underperform Rating - Moomoo
Form 8K Praxis Precision Medicines Inc For: 6 August By Investing.com - Investing.com Nigeria
Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside - TradingView
Praxis Precision Medicines stock hits 52-week high at 366.7 USD - Investing.com Nigeria
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... - Yahoo Finance
Earnings call transcript: Praxis Precision Medicines beats Q2 2026 EPS forecast as shares jump - Investing.com Nigeria
PRAXIS PRECISION MEDICINES, INC. : RBC RAISES TARGET PRICE TO $462 FROM $449 - Bitget
PRAXIS PRECISION MEDICINES, INC. : BAIRD RAISES TARGET PRICE TO $514 FROM $400 - Bitget
Needham & Company LLC Raises Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $582.00 - MarketBeat
Praxis Precision Medicines gains as investors refocus on late-stage CNS pipeline and upcoming FDA catalysts - Quiver Quantitative
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Better-Than-Expected Earnings - marketbeat.com
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):